Regeneron(REGN) Prnewswire·2025-01-28 10:45Core Viewpoint - A class action securities lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud that affected investors between November 2, 2023, and October 30, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Regeneron made false statements and concealed payments made to distributors to cover credit card fees, which misled investors about the true sales figures of Eylea [2]. - It is alleged that these payments allowed Regeneron to offer price concessions that lowered Eylea's selling price, thus misleadingly boosting reported sales figures [2]. - The complaint also states that Regeneron failed to report these payments as price concessions, resulting in an overstatement of the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [2]. Group 2: Investor Information - Investors who suffered losses during the specified time frame have until March 10, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, indicating its expertise in handling complex cases [4].